BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10076772)

  • 21. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis.
    Qian J; Niu J; Li M; Chiao PJ; Tsao MS
    Cancer Res; 2005 Jun; 65(12):5045-53. PubMed ID: 15958547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours.
    Uemura K; Hiyama E; Murakami Y; Kanehiro T; Ohge H; Sueda T; Yokoyama T
    Oncol Rep; 2003; 10(2):277-83. PubMed ID: 12579258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis.
    Moore PS; Orlandini S; Zamboni G; Capelli P; Rigaud G; Falconi M; Bassi C; Lemoine NR; Scarpa A
    Br J Cancer; 2001 Jan; 84(2):253-62. PubMed ID: 11161385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD44 isoforms expression in intraductal and invasive pancreatic cancer and its correlation to p53 gene mutations.
    Tomaszewska R; Nowak K; Stachura J
    Pol J Pathol; 1999; 50(3):145-53. PubMed ID: 10624116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular mechanism involved in increased expression of sialyl Lewis antigens in ductal carcinoma of the pancreas.
    Nakamori S; Nishihara S; Ikehara Y; Nagano H; Dono K; Sakon M; Narimatsu H; Monden M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):425-32. PubMed ID: 10606190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region.
    Sturm PD; Hruban RH; Ramsoekh TB; Noorduyn LA; Tytgat GN; Gouma DJ; Offerhaus GJ
    J Pathol; 1998 Nov; 186(3):247-53. PubMed ID: 10211112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer.
    Yamasawa K; Nio Y; Dong M; Yamaguchi K; Itakura M
    Clin Cancer Res; 2002 Aug; 8(8):2563-9. PubMed ID: 12171884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma.
    Isa T; Tomita S; Nakachi A; Miyazato H; Shimoji H; Kusano T; Muto Y; Furukawa M
    Hepatogastroenterology; 2002; 49(45):604-8. PubMed ID: 12063950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.
    Adsay NV; Basturk O; Cheng JD; Andea AA
    Semin Radiat Oncol; 2005 Oct; 15(4):254-64. PubMed ID: 16183479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas.
    Zhang SY; Ruggeri B; Agarwal P; Sorling AF; Obara T; Ura H; Namiki M; Klein-Szanto AJ
    Arch Pathol Lab Med; 1994 Feb; 118(2):150-4. PubMed ID: 8311654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in K-ras and p53 gene mutations among pancreatic adenocarcinomas associated with regional environmental pollution.
    Soliman AS; Lo AC; Banerjee M; El-Ghawalby N; Khaled HM; Bayoumi S; Seifeldin IA; Abdel-Aziz A; Abbruzzese JL; Greenson JK; Hamilton SR
    Carcinogenesis; 2007 Aug; 28(8):1794-9. PubMed ID: 17575320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer.
    Catalano T; Curia MC; Aceto G; Verginelli F; Cascinu S; Cama A; Mariani-Costantini R; Teti D; Battista P
    Oncol Rep; 2005 Sep; 14(3):625-31. PubMed ID: 16077965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
    Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
    JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 and K-RAS alterations in pancreatic epithelial cell lesions.
    Kalthoff H; Schmiegel W; Roeder C; Kasche D; Schmidt A; Lauer G; Thiele HG; Honold G; Pantel K; Riethmüller G
    Oncogene; 1993 Feb; 8(2):289-98. PubMed ID: 8426738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p16 and p53 gene alterations and accumulations in the malignant evolution of intraductal papillary-mucinous tumors of the pancreas.
    Wada K
    J Hepatobiliary Pancreat Surg; 2002; 9(1):76-85. PubMed ID: 12021900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Undifferentiated carcinoma of the pancreas: analysis of intermediate filament profile and Ki-ras mutations provides evidence of a ductal origin.
    Hoorens A; Prenzel K; Lemoine NR; Klöppel G
    J Pathol; 1998 May; 185(1):53-60. PubMed ID: 9713360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumor stage in human pancreatic carcinoma.
    Motojima K; Urano T; Nagata Y; Shiku H; Tsunoda T; Kanematsu T
    Am J Gastroenterol; 1991 Dec; 86(12):1784-8. PubMed ID: 1962623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.